Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1547
Abstract: We predicted the drug–drug interaction (DDI) potential of siponimod in presence of cytochrome P450 (CYP)2C9/CYP3A4 inhibitors/inducers in subjects with different CYP2C9 genotypes by physiologically‐based pharmacokinetic (PK) modeling. The model was established using in vitro and… read more here.
Keywords: siponimod; drug interaction; potential siponimod; drug ... See more keywords
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Neurology"
DOI: 10.1007/s00415-025-13300-z
Abstract: Sphingosine-1-phosphate (S1P) receptor modulators, regulating the S1P/S1PR pathway, lead to lymphocyte sequestration in lymphoid organs, which results in peripheral lymphopenia. This study evaluates the degree of lymphopenia induced by S1P modulators in people with Multiple… read more here.
Keywords: s1p receptor; lymphopenia; siponimod; receptor modulators ... See more keywords
Siponimod supports remyelination in the non-supportive environment
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-87825-8
Abstract: Inflammatory demyelination, a hallmark of multiple sclerosis (MS) lesions, leads to functional impairments and progressive axonal loss over time. Although remyelination is thought to protect axons, endogenous regenerative processes are often incomplete or fail entirely… read more here.
Keywords: supportive environment; siponimod; remyelination non; remyelination ... See more keywords
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2078103
Abstract: Abstract Objective Identification of the phenotypic transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is often delayed due to disease complexity and an unwillingness to withdraw RRMS disease-modifying therapies (DMTs), driven… read more here.
Keywords: cost; treatment; multiple sclerosis; siponimod ... See more keywords
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s122249
Abstract: Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared… read more here.
Keywords: siponimod; treatment; evidence; multiple sclerosis ... See more keywords
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
Sign Up to like & getrecommendations! Published in 2022 at "Patient preference and adherence"
DOI: 10.2147/ppa.s221882
Abstract: Introduction A number of disease-modifying therapies have been approved for use in relapsing-remitting multiple sclerosis (MS) in the past two decades. However, only few treatment options are available for patients with secondary progressive multiple sclerosis… read more here.
Keywords: progressive multiple; secondary progressive; efficacy safety; multiple sclerosis ... See more keywords